Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.
- DOI
- 10.1080/13543784.2026.2687030
- Published
- 2026 Jun
- Container
- Expert opinion on investigational drugs
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13543784.2026.2687030,
title = {Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.},
author = {Iannone LF and Romozzi M and Pani L and Tascedda F},
year = {2026},
journal = {Expert opinion on investigational drugs},
doi = {10.1080/13543784.2026.2687030},
url = {https://doi.org/10.1080/13543784.2026.2687030}
}RIS
TY - JOUR TI - Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges. AU - Iannone LF AU - Romozzi M AU - Pani L AU - Tascedda F PY - 2026 JO - Expert opinion on investigational drugs DO - 10.1080/13543784.2026.2687030 UR - https://doi.org/10.1080/13543784.2026.2687030 ER -
APA
LF, I., M, R., L, P., & F, T. (2026). Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2026.2687030
Source records
- pubmed · retrieved 2026-09-25T12:54:37.241Z